Cardiovascular magnetic resonance for suspected cardiac amyloidosis: where are we now?

Jean Michel Saad, Ahmed Ibrahim Ahmed, Yushui Han, Maan Malahfji, Ahmed Aljizeeri, Mouaz H. Al-Mallah

Research output: Contribution to journalReview articlepeer-review

Abstract

Cardiac amyloidosis (CA) is an underdiagnosed form of restrictive cardiomyopathy leading to a rapid progression into heart failure. Evaluation of CA requires a multimodality approach making use of echocardiography, cardiac magnetic imaging (CMR), and nuclear imaging. With superior tissue characterization, high-resolution imaging, and precise cardiac assessment, CMR has emerged as a versatile tool in the workup of cardiac amyloidosis with a wide array of parameters both visual and quantitative. This includes late gadolinium enhancement patterns, T1/T2 mapping, and extracellular volume (ECV) measurement providing robust diagnostic accuracies, patient stratification, and prognostication. Recent advancements have introduced new measures able to identify early disease, track disease progression, and response to therapy positioning CMR as an instrumental imaging modality in the era of rising interest in CA screening and emerging effective therapies.

Original languageEnglish (US)
JournalHeart Failure Reviews
DOIs
StateAccepted/In press - 2022

Keywords

  • CMR
  • Cardiac amyloidosis
  • ECV
  • LGE
  • T1 mapping
  • T2 mapping

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Cardiovascular magnetic resonance for suspected cardiac amyloidosis: where are we now?'. Together they form a unique fingerprint.

Cite this